R-Pag 12.5 mg (Tablet)
Unit Price: ৳ 250.00 (1 x 10: ৳ 2,500.00)
Strip Price: ৳ 2,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Eltrombopag olamine |
| Company | Renata limited |
| Also available as |
Indications
- Treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia
- Treatment of thrombocytopenia in patients with hepatitis C infection
- Treatment of severe aplastic anemia
- Limitations of use: R-Pag is not indicated for the treatment of patients with myelodysplastic syndromes (MDS)
Pharmacology
- Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist
- Interacts with the transmembrane domain of the human TPO-receptor
- Induces proliferation and differentiation from bone marrow progenitor cells
- Increases platelet production
Dosage & Administration
- Oral route of administration
- Can be taken without a meal or with a meal low in calcium
- Specific dosages for different conditions and patient demographics
- Instructions for dose adjustments
Interaction
- Drug interaction with medication: Take eltrombopag at least 2 hours before or 4 hours after medications or products containing polyvalent cations
- Drug interaction with food and others: Take eltrombopag at least 2 hours before or 4 hours after any calcium-rich foods
Contraindications
- Contraindicated in patients with known hypersensitivity to eltrombopag or any components of this product
Side Effects
- Common side effects include anemia, nausea, pyrexia, ALT increased, cough, fatigue, headache, and diarrhea
Pregnancy & Lactation
- Insufficient data available to assess drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes
- Not recommended for breastfeeding due to potential serious adverse reactions
Precautions & Warnings
- Increased risk of hepatic decompensation in patients with chronic hepatitis C
- Increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia
- Portal vein thrombosis reported in patients with chronic liver disease receiving eltrombopag
- Need for regular monitoring of liver function and platelet counts
Use in Special Populations
- Safety and efficacy not established in pediatric patients below the age of 1 year with ITP
- Safety and efficacy not established in pediatric patients with thrombocytopenia associated with chronic hepatitis C and refractory severe aplastic anemia
Overdose Effects
- Excessive increase in platelet counts may lead to thrombotic or thromboembolic complications
- Consider oral administration of metal cation-containing preparation in case of overdose
Therapeutic Class
- Haemostatic drugs
Storage Conditions
- Store in a cool (below 25°C) and dry place protected from light
- Keep away from the reach of children